专访丨“中国不仅是全球战略市场，更是全球创新枢纽”——访阿斯利康全球执行副总裁尹思睿

Core Viewpoint - AstraZeneca views China not only as a global strategic market but also as a global innovation hub, driven by its market scale, business environment, and innovation capabilities [1]. Group 1: Investment and Market Presence - AstraZeneca has invested over $5 billion in China since entering the market in 1993, establishing a comprehensive industry chain covering research, production, and commercial operations [1]. - China has become AstraZeneca's second-largest market globally, significantly supporting its global research efforts and playing a crucial role in the international pharmaceutical supply system [1]. Group 2: Innovation and Growth Factors - The past four years have seen a doubling in the number of drugs under research in China, with approximately one-third of global drug authorization transactions involving Chinese biopharmaceutical companies, highlighting China's growing importance in global business expansion for multinational companies [2]. - Factors such as consistent policy support, the continuous stimulation of innovation potential, and the effective utilization of talent reserves contribute to China's unique market advantages [2]. Group 3: Future Outlook - AstraZeneca expresses confidence in China's long-term development prospects and business environment, anticipating that forward-looking policies will further promote deeper international cooperation [2].